Document Detail


Early and late haemodynamic and morphological effects of angiotensin II subtype 1 receptor blockade during genetic hypertension development.
MedLine Citation:
PMID:  7594426     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To investigate the haemodynamic and morphological effects resulting from the chronic administration to young spontaneously hypertensive rats (SHR) of a new selective angiotensin II subtype 1 (AT1) receptor antagonist, SR 47436/BMS-186295 (SR/BMS) both during and after the treatment period. METHODS: SR/BMS (60 mg/kg per day, orally) or distilled water was chronically (from 4 to 20 weeks of age) administered to SHR. At age 8, 14, 20 and 28 weeks the effects of SR/BMS on the systemic and regional haemodynamic (radioactive microsphere technique) and the cardiac and vascular morphological parameters (automatic image analysis) were investigated. RESULTS: SR/BMS limited genetic hypertension development and opposed the age-related rises in total peripheral and regional vascular resistances. Simultaneously, it limited the age-related increases in heart weight, left ventricular cross-sectional area and collagen content. Age-related increases in aortic media thickness and amount of collagen were also significantly reduced, whereas aortic compliance was increased. Eight weeks after withdrawal of treatment the antihypertensive effect of SR/BMS, although attenuated, and the limitation of cardiac and vascular remodelling, persisted. CONCLUSIONS: Early AT1 receptor blockade in SHR opposes genetic hypertension development during the treatment period and persistently after its interruption. Prevention of genetic hypertension development during the treatment period can be accounted for by the limitation of the age-related development of the haemodynamic and morphological abnormalities, whereas the persistence of the antihypertensive effect observed after drug withdrawal is due mainly to a maintained prevention of the development of the cardiovascular morphological alterations.
Authors:
E Vacher; P Fornes; C Richer; P Bruneval; D Nisato; J F Giudicelli
Related Documents :
1575946 - Role of autonomic function in the antihypertensive effect of vasopressin withdrawal in ...
10826566 - Increased proximal tubule nhe-3 and h+-atpase activities in spontaneously hypertensive ...
7640396 - Mechanical and contractile properties of in situ localized mesenteric arteries in normo...
3661746 - Hypertension in shr rats: contribution of maternal environment.
18045096 - Atherosclerosis and arterial blood pressure in mice.
9118406 - Preliminary noninvasive back-pressure recordings of bladder pressure.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of hypertension     Volume:  13     ISSN:  0263-6352     ISO Abbreviation:  J. Hypertens.     Publication Date:  1995 Jun 
Date Detail:
Created Date:  1995-11-30     Completed Date:  1995-11-30     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8306882     Medline TA:  J Hypertens     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  675-82     Citation Subset:  IM    
Affiliation:
Département de Pharmacologie, Faculté de Médecine Paris-Sud, Le Kremlin-Bicêtre, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antihypertensive Agents / pharmacology
Aorta / pathology
Biphenyl Compounds / pharmacology*
Hemodynamics / drug effects*
Hypertension / genetics*,  pathology,  physiopathology*
Male
Myocardium / pathology
Rats
Rats, Inbred SHR
Receptors, Angiotensin / antagonists & inhibitors*
Tetrazoles / pharmacology*
Time Factors
Chemical
Reg. No./Substance:
0/Antihypertensive Agents; 0/Biphenyl Compounds; 0/Receptors, Angiotensin; 0/Tetrazoles; 138402-11-6/irbesartan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Serial changes in blood pressure, renal function, endothelin and lipoprotein (a) during the first 9 ...
Next Document:  Angiotensin II induces cardiovascular hypertrophy in perindopril-treated rats.